Baxter International Inc.
BAX
Rank in Stocks
#1653
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Share Price
$25.03
Last synced: 2026-10-19
Market Cap
$12.94B
Change (1 day)
-1.03%
Change (1 year)
8.19%
Country
US
Trade Baxter International Inc. (BAX)
Category
Healthcare
P/E ratio for Baxter International Inc. (BAX)
P/E ratio as of October 2026 TTM: -12.16
According to Baxter International Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.16. At the end of 2023 the company had a P/E ratio of 7.37.
P/E ratio history for Baxter International Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -12.16 | -46.92% |
| 2024 | -22.91 | -411.12% |
| 2023 | 7.37 | -169.76% |
| 2022 | -10.56 | -131.46% |
| 2021 | 33.56 | -9.45% |
| 2020 | 37.06 | -12.84% |
| 2019 | 42.52 | 87.03% |
| 2018 | 22.73 | -61.01% |
| 2017 | 58.30 | 1,095.73% |
| 2016 | 4.88 | -77.30% |
| 2015 | 21.48 | 148.51% |
| 2014 | 8.64 | -15.23% |
| 2013 | 10.20 | 18.87% |
| 2012 | 8.58 | 24.73% |
| 2011 | 6.88 | -39.81% |
| 2010 | 11.43 | 30.20% |
| 2009 | 8.78 | -2.85% |
| 2008 | 9.03 | -24.08% |
| 2007 | 11.90 | 1.26% |
| 2006 | 11.75 | -11.68% |
| 2005 | 13.31 | -55.18% |
| 2004 | 29.69 | 170.37% |
| 2003 | 10.98 | 23.45% |
| 2002 | 8.89 | -65.50% |
| 2001 | 25.78 | 36.47% |
| 2000 | 18.89 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 47.48 | -490.51% |
US
|
|
| 27.43 | -325.55% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -567.89% |
US
|
|
| - | - |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.